[1] JIANG W, KIM B Y, RUTKA J T, et al．Advances and challenges of nanotechnology-based drug delivery systems[J]．Expert Opin Drug Deliv, 2007, 4(6): 621-633．
[2] MEDLICOTT N J, WALDRON N A, FOSTER T P．Sustained release veterinary parenteral products [J]．Adv Drug Deliv Rev, 2004, 56(10): 1345-1365．
[3] 董 敏, 王爱萍, 邵亚婷, 等．美欧日复杂注射剂技术要求及案例分析[J]．中国医药工业杂志, 2019, 50(10): 1228-1236．
[4] 张 雪, 齐宜广, 武玉杰, 等．新型注射剂的国内外研发进展[J]．药学进展, 2018, 42(12): 897-904.
[5] BITTERLICH A, LAABS C, KRAUTSTRUNK I, et al．Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling [J]．Eur J Pharm Biopharm, 2015, 92: 171-179．
[6] KAPLAN G, CASOY J, ZUMMO J．Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia[J]．Patient Prefer Adher, 2013, 7: 1171-1180．
[7] SPREEN W R, MARGOLIS D A, POTTAGE J C Jr．Long-acting injectable antiretrovirals for HIV treatment and prevention [J]．Curr Opin HIV AIDS, 2013, 8(6): 565-571．
[8] KULKARNI T A, BADE A N, SILLMAN B, et al．A yearlong extended release nanoformulated cabotegravir prodrug[J]．Nat Mater, 2020, 19(8): 910-920．
[9] 岳鹏飞, 刘 阳, 谢 锦, 等．药物纳米晶体制备技术 30 年发展回顾与展望[J]．药学学报, 2018, 53(4): 529-537．
[10] STELLA V J．Prodrugs: some thoughts and current issues[J]．J Pharm Sci, 2010, 99(12): 4755-4765．
[11] EABORN C．Compendium of chemical terminology:IUPAC recommendations [J]．J Organomet Chem, 1988,356(2): C76-C77．
[12] HUTTUNEN K M, RAUNIO H, RAUTIO J．Prodrugsfrom serendipity to rational design [J]．Pharmacol Rev,2011, 63(3): 750-771．
[13] NASSER J, THOMAS B．Haloperidol decanoate [J]．Aust N Z J Psychiatry, 1989, 23(3): 311-312．
[14] LUO J P, HUBBARD J W, MIDHA K K．Studies on the mechanism of absorption of depot neuroleptics: fluphenazine
decanoate in sesame oil [J]．Pharm Res, 1997, 14: 1079-1084．
[15] HOUGH D, LINDENMAYER J P, GOPAL S, et al．Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia [J]．Progr Neuro-Psychopharmacol Biol Psychiatr, 2009, 33(6): 1022-1031．
[16] ROHDE M, M?RK N, H?KANSSON A E, et al．Biological conversion of aripiprazole lauroxil – an N-acyloxymethyl aripiprazole prodrug [J]．Results Pharma Sci, 2014, 4: 19-25．
[17] VAN DER VIES J．Implications of basic pharmacology in the therapy with esters of nandrolone [J]．Acta Endocrinol
Suppl (Copenh), 1985, 271: 38-44．
[18] HO M J, LEE D R, IM S H, et al．Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery
[J]．Int J Pharm, 2018, 543(1/2): 52-59．
[19] HILAIRE J R, BADE A N, SILLMAN B, et al．Creation of a long-acting rilpivirine prodrug nanoformulation [J]．J Control Release, 2019, 311/312: 201-211．
[20] FRAN?OIS M K J, DRIES W M A C, BASSTANIE E D G．Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters: US, 6555544 [P]．2003-04-29．
[21] GEORGE M, GHOSH I．Identifying the correlation between drug/stabilizer properties and critical quality attributes
(CQAs) of nanosuspension formulation prepared by wet media milling technology [J]．Eur J Pharm Sci, 2013,48(1/2): 142-152．
[22] KOO O M Y．Application challenges and examples of new excipients in advanced drug delivery systems [J]．Am Pharm Rev, 2011, 14(2): 60-68．
[23] BAERT L, VAN 'T KLOOSTER G, DRIES W, et al．Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment[J]．Eur J Pharm Biopharm, 2009, 72(3): 502-508．
[24] CHAMANZA R, DARVILLE N, VAN HEERDEN M, et al．Comparison of the local tolerability to 5 long-acting drug nanosuspensions with different stabilizing excipients,following a single intramuscular administration in the rat[J]．Toxicol Pathol, 2018, 46(1): 85-100．
[25] HIRANO K, ICHIHASHI T, YAMADA H．Studies on the absorption of practically water-insoluble drugs following injection. III. Intramuscular absorption from aqueous nonionic surfactant solutions in rats [J]．Chem Pharm Bull,1981, 29(3): 834-843．
[26] MATSUDA T．ABILIFY MAINTENA?(aripiprazole) for extended-release antipsychotic injectable suspension for schizophrenia [J]．Drug Deliv Syst, 2018, 33(2): 151-155．
[27] MALLIKAARJUN S, KANE J M, BRICMONT P, et al．Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallelarm,multiple-dose study [J]．Schizophr Res, 2013, 150(1):281-288．
[28] MITCHELL M, KOTHARE P, BERGSTROM R, et al．Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia [J]．Clin Ther, 2013, 35(12): 1890-1908．
[29] GOMENI R, LAFFONT CM, HEIDBREDER C. A dose switching simulation analyses from Invega? Sustenna? or Risperdal? Consta? to RBP-7000, a new sustained-release formulation of risperidone [J]．Clin Pharmacol Ther, 2014,55(1): 93-103．
[30] SAMTANI M N, VERMEULEN A, STUYCKENS K．Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia [J]．Clin Pharmacokinet, 2009, 48(9): 585-600．
[31] FDA．Clinical pharmacology and biopharmaceutics review[EB/OL]．[2015-04-19]．http://www．accessdata．fda．gov/drugsatfda．[32] FDA．Invega TrinzaTM (Paliperidone palmitate extendedrelease injectable suspension, for intramuscular use)highlights of prescribing information [EB/OL]．[2015-10-20]．http://www．accessdata．fda．gov/drugsatfda_docs/label/2015/207946s000lbl．pdf．
[33] VAN 'T KLOOSTER G, HOEBEN E, BORGHYS H, et al．Pharmacokinetics and disposition of rilpivirine (TMC278)nanosuspension as a long-acting injectable antiretroviral formulation [J]．Antimicrob Agents Chemother, 2010,54(5): 2042-2050．
[34] BAHAR F G, OHURA K, OGIHARA T, et al．Species difference of esterase expression and hydrolase activity in plasma [J]．J Pharm Sci, 2012, 101(10): 3979-3988．
[35] ROSSENU S , CLETON A , HOUGH D , e t a l．Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia [J]．Clin Pharmacol Drug Dev, 2015,4(4): 270-278．
[36] MCDONNELL D P, DETKE H C, BERGSTROM R F, et al．Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism [J]．BMC Psychiatry, 2010, 10: 45．
[37] CHAUDHARY K, PATEL M M, MEHTA P J．Long-acting injectables: current perspectives and future promise [J]．Crit Rev Ther Drug Carrier Syst, 2019, 36(2): 137-181．
[38] FDA．Dissolution Methods for 2019 [EB/OL]．https://www．accessdata．fda．gov/scripts/cder/dissolution/．
[39] RUDD N D , HELMY R, DORMER P G , e t a l．Probing in vitro release kinetics of long-acting injectable nanosuspensions via flow-NMR spectroscopy [J]．Mol Pharm, 2020, 17(2): 530-540．
[40] FORREST W P, REUTER K G, SHAH V, et al．USP apparatus 4: a valuable in vitro tool to enable formulation development of long-acting parenteral (LAP)nanosuspension formulations of poorly water-soluble compounds [J]．AAPS PharmSciTech, 2018, 19(1): 413-424．
[41] JANAS C, MAST M P, KIRSAMER L, et al．The dispersion releaser technology is an effective method for testing drug
release from nanosized drug carriers [J]．Eur J Pharm Biopharm, 2017, 115: 73-83．
[42] FDA．Extended release oral dosage forms: development,evaluation, and application of in vitro/in vivo correlations
[EB/OL]．[1997-09]．https://www．fda．gov/regulatoryinformation/search-fda-guidance-documents/extendedrelease-oral-dosage-forms-development-evaluation-andapplication-vitroin-vivo-correlations．
[43] D'SOUZA S, FARAJ J A, GIOVAGNOLI S, et al．IVIVC from long acting olanzapine microspheres [J]．Int J Biomater, 2014, 2014: 407065．
[44] SHEN J, CHOI S, QU W, et al．In vitro-in vivo correlation of parenteral risperidone polymeric microspheres [J]．J
Control Release, 2015, 218: 2-12．
[45] RAWAT A, BHARDWAJ U, BURGESS D J．Comparison of in vitro-in vivo release of Risperdal? Consta? microspheres[J]．Int J Pharm, 2012, 434(1/2): 115-121．
[46] ANDHARIYA J V, JOG R, SHEN J, et al．Development of level A in vitro-in vivo correlations for peptide loaded PLGA
microspheres [J]．J Control Release, 2019, 308: 1-13．
[47] JABLONKA L, ASHTIKAR M, GAO G, et al．Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans [J]．J Control Release, 2019, 308: 57-70．
[48] PAQUETTE S M, DAWIT H, HICKEY M B, et al．Longacting atypical antipsychotics: characterization of the local tissue response [J]．Pharm Res, 2014, 31(8): 2065-2077．
[49] DARVILLE N, VAN HEERDEN M, VYNCKIER A,et al．Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats [J]．J Pharm Sci, 2014, 103(7):2072-2087．
[50] ZHOU T, SU H, DASH P, e t a l．C r e a t i o n o f a nanoformulated cabotegravir prodrug with improved antiretroviral profiles [J]．Biomaterials, 2018, 151: 53-65．
[51] KADIU I , NOWACEK A, MCMILLAN J , et a l．Macrophage endocytic trafficking of antiretroviral nanoparticles [J]．Nanomedicine, 2011, 6(6): 975-994．
[52] DARVILLE N, VAN HEERDEN M, MARI?N D, et al．The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustainedrelease paliperidone palmitate suspension [J]．J Control Release, 2016, 230: 95-108．
[53] MAGNUSSON M O, SAMTANI M N, PLAN E L, et al．Population pharmacokinetics of a novel once-every 3 months intramuscular formulation of paliperidone palmitate in patients with schizophrenia [J]．Clin Pharmacokinet, 2017,56(4): 421-433．
[54] SMITH N, BADE A N, SONI D, et al．A long acting nanoformulated lamivudine ProTide [J]．Biomaterials,2019, 223: 119476．
[55] GUO D, ZHANG G, WYSOCKI T A, et al．Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance [J]．J Virol, 2014,88(17): 9504-9513．
[56] EDAGWA B, MCMILLAN J, SILLMAN B, et al．Longacting slow effective release antiretroviral therapy [J]．Expert Opinion Drug Deliv, 2017, 14(11): 1281-1291．
[57] SILLMAN B, BADE A N, DASH P K, et al．Creation of a long-acting nanoformulated dolutegravir [J]．Nat Commun,2018, 9: 443．
[58] DARVILLE N, VAN HEERDEN M, ERKENS T, et al．Modeling the time course of the tissue responses to intramuscular long-acting paliperidone palmitate nano-/microcrystals and polystyrene microspheres in the rat [J]．Toxicol Pathol, 2016, 44(2): 189-210．
[59] RABINOW B E. Nanosuspensions in drug delivery [J]. Nat Rev Drug Discov, 2004, 3(9): 785-796.
[60] KINNUNEN H M, MRSNY R J．Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site [J]．J Control
Release, 2014, 182: 22-32．
[61] 窦春阳, 范学文, 吴若芬, 等．免疫荧光细胞化学染色联合激光扫描共聚焦显微技术对脑膜癌病的诊断价值[J]．中国现代神经疾病杂志, 2011, 11(5): 534-537．
[62] EVANS C L, XIE X S．Coherent anti-stokes Raman scattering microscopy: chemical imaging for biology and medicine [J]．Annu Rev Anal Chem, 2008, 1: 883-909．
[63] EL-DIASTY F．Coherent anti-Stokes Raman scattering:spectroscopy and microscopy [J]．Vib Spectrosc, 2011,55(1): 1-37．
[64] POPE I, PAYNE L, ZORINIANTS G, et al．Coherent anti-Stokes Raman scattering microscopy of single nanodiamonds[J]．Nat Nanotechnol, 2014, 9(11): 940-946．
[65] ALFONSO-GARCíA A, MITTAL R, LEE E S, et al．Biological imaging with coherent Raman scattering microscopy: a tutorial [J]．J Biomed Opt, 2014, 19(7):071407．
[66] JUCKER B M, ALSAID H, RAMBO M, et al．Multimodal imaging approach to examine biodistribution kinetics of cabotegravir (GSK1265744) long acting parenteral formulation in rat [J]．J Control Release, 2017, 268: 102-112．
[67] GROSECLOSE M R, CASTELLINO S. Intramuscular and subcutaneous drug depot characterization of a long-acting cabotegravir nanoformulation by MALDI IMS [J]. Int J Mass Spectrom, 2018, S138738061730372X.